Message Font: Serif | Sans-Serif
No. of Recommendations: 0
I realize this topic is way off topic for this board.

I would like to add that.

Omeros has breakthrough status for both HSTC-TMA and Igan.

This means both are orphan drug categories, serious death risk, and no current treatment.

OMS721 is the only drug that has breakthrough designation for these 2 potential indications.

Breakthrough designation is rare. I believe less than 500 times the FDA has given this designation, likely much less.

Having 1 drug candidate with 2 breakthrough designations is even rarer. My guess less than 25 times.

Being a small company with a breakthrough drug for 2 indications much smaller. Likely less than 5.

Many breakthrough designation drugs never get approved. But the approval rate is much higher than the general drug development population.
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.